© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Monopar Therapeutics Inc. (MNPR) stock declined over -1.12%, trading at $109.09 on NASDAQ, down from the previous close of $110.33. The stock opened at $108.59, fluctuating between $105.10 and $111.34 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 27, 2026 | 110.29 | 112.16 | 106.34 | 110.33 | 339.77K |
| Jul 24, 2026 | 105.47 | 110.23 | 103.00 | 109.87 | 229.8K |
| Jul 23, 2026 | 110.86 | 111.02 | 101.00 | 105.70 | 297.91K |
| Jul 22, 2026 | 113.03 | 116.64 | 110.28 | 112.48 | 439.86K |
| Jul 21, 2026 | 105.89 | 113.94 | 105.89 | 113.57 | 247.63K |
| Jul 20, 2026 | 112.46 | 115.00 | 105.31 | 105.90 | 121.67K |
| Jul 17, 2026 | 106.61 | 111.94 | 104.00 | 111.12 | 265.22K |
| Jul 16, 2026 | 108.17 | 110.00 | 105.32 | 108.52 | 193.68K |
| Jul 15, 2026 | 99.45 | 109.31 | 97.93 | 108.69 | 177.05K |
| Jul 14, 2026 | 103.68 | 108.76 | 98.30 | 99.79 | 498.23K |
| Jul 13, 2026 | 106.15 | 106.90 | 100.50 | 103.33 | 214.65K |
| Jul 10, 2026 | 103.28 | 107.41 | 97.97 | 106.60 | 149.26K |
| Jul 09, 2026 | 99.04 | 112.57 | 97.71 | 104.50 | 336.86K |
| Jul 08, 2026 | 93.87 | 100.03 | 88.33 | 99.27 | 298.02K |
| Jul 07, 2026 | 97.11 | 98.96 | 93.86 | 95.22 | 163.56K |
| Jul 06, 2026 | 98.33 | 101.09 | 96.61 | 97.12 | 103.87K |
| Jul 02, 2026 | 95.44 | 100.00 | 93.59 | 97.79 | 188.27K |
| Jul 01, 2026 | 93.83 | 100.33 | 93.75 | 95.03 | 177.44K |
| Jun 30, 2026 | 96.41 | 97.98 | 91.90 | 92.59 | 111.8K |
| Jun 29, 2026 | 87.68 | 95.75 | 86.30 | 94.56 | 119.87K |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Employees | 22 |
| Beta | 1.48 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |